- Home
- GMAB vs DAKT Comparison
GMAB vs DAKT Comparison
Compare GMAB & DAKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- DAKT
- Stock Information
- Founded
- GMAB 1999
- DAKT 1968
- Country
- GMAB Denmark
- DAKT United States
- Employees
- GMAB N/A
- DAKT N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- DAKT Office Equipment/Supplies/Services
- Sector
- GMAB Health Care
- DAKT Industrials
- Exchange
- GMAB Nasdaq
- DAKT Nasdaq
- Market Cap
- GMAB 12.8B
- DAKT 680.6M
- IPO Year
- GMAB N/A
- DAKT 1994
- Fundamental
- Price
- GMAB $20.95
- DAKT $14.84
- Analyst Decision
- GMAB Buy
- DAKT Strong Buy
- Analyst Count
- GMAB 9
- DAKT 1
- Target Price
- GMAB $39.17
- DAKT $26.00
- AVG Volume (30 Days)
- GMAB 1.5M
- DAKT 510.2K
- Earning Date
- GMAB 05-08-2025
- DAKT 06-25-2025
- Dividend Yield
- GMAB N/A
- DAKT N/A
- EPS Growth
- GMAB 276.13
- DAKT N/A
- EPS
- GMAB 18.36
- DAKT 0.04
- Revenue
- GMAB $3,230,902,140.00
- DAKT $799,806,000.00
- Revenue This Year
- GMAB $17.69
- DAKT N/A
- Revenue Next Year
- GMAB $14.81
- DAKT $4.86
- P/E Ratio
- GMAB $11.30
- DAKT $406.38
- Revenue Growth
- GMAB 25.21
- DAKT N/A
- 52 Week Low
- GMAB $17.24
- DAKT $10.24
- 52 Week High
- GMAB $28.96
- DAKT $19.89
- Technical
- Relative Strength Index (RSI)
- GMAB 55.72
- DAKT 55.21
- Support Level
- GMAB $20.73
- DAKT $15.10
- Resistance Level
- GMAB $21.42
- DAKT $16.14
- Average True Range (ATR)
- GMAB 0.45
- DAKT 0.59
- MACD
- GMAB 0.11
- DAKT -0.05
- Stochastic Oscillator
- GMAB 81.62
- DAKT 36.27
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About DAKT Daktronics Inc.
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.